BFM
APLS

Boothbay Fund Management’s Apellis Pharmaceuticals APLS Stock Holding History

Boothbay Fund Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-58,600
Closed -$1.69M – 1480
2024
Q3 		$1.69M Buy
+58,600
New +$2.17M 0.04% 579
2024
Q2 		– Sell
-81,700
Closed -$4.8M – 1504
2024
Q1 		$4.8M Buy
+81,700
New +$5.21M 0.09% 238
2023
Q4 		– Sell
-8,300
Closed -$316K – 1637
2023
Q3 		$316K Sell
8,300
-170,300
-95% -$7.48M 0.01% 1227
2023
Q2 		$16.3M Buy
+178,600
New +$15.4M 0.36% 34
2023
Q1 		– Sell
-30,800
Closed -$1.59M – 2110
2022
Q4 		$1.59M Sell
30,800
-66,500
-68% -$3.53M 0.04% 692
2022
Q3 		$6.65M Buy
97,300
+66,500
+216% +$3.94M 0.17% 111
2022
Q2 		$1.39M Hold
30,800
– – 0.04% 685
2022
Q1 		$1.56M Buy
+30,800
New +$1.36M 0.04% 687
2021
Q4 		– Sell
-35,500
Closed -$1.17M – 1843
2021
Q3 		$1.17M Buy
35,500
+1,400
+4% +$78.7K 0.03% 685
2021
Q2 		$2.15M Buy
+34,100
New +$1.76M 0.07% 356
2020
Q2 		– Sell
-118
Closed -$316K – 953
2020
Q1 		$316K Sell
118
-376
-76% -$13.3K 0.03% 559
2019
Q4 		$1.51M Buy
+494
New +$13.7K 0.13% 215

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Boothbay Fund Management's APLS Position: Q1 2026 in Review

Boothbay Fund Management increased its Apellis Pharmaceuticals (APLS) stake by 757% in Q1 2026, buying an estimated $3.49M and bringing the position to 183,522 shares worth $7.38M. The position accounts for 0.1% of the portfolio, ranked #208.

Boothbay Fund Management first reported a position in APLS in Q4 2018 and has held it in 14 quarters since. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Boothbay Fund Management held 183,522 shares of Apellis Pharmaceuticals worth $7.38M as of Q1 2026.
  • Boothbay Fund Management bought 162,107 Apellis Pharmaceuticals shares in Q1 2026, an estimated $3.49M.
  • Apellis Pharmaceuticals made up 0.1% of Boothbay Fund Management's portfolio in Q1 2026, its #208 holding.
  • Boothbay Fund Management first reported a position in Apellis Pharmaceuticals in Q4 2018 and has held it in 14 quarters since.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.